ARTICLE | Clinical News
Fampridine-SR: Additional Phase III data
September 29, 2008 7:00 AM UTC
Acorda Therapeutics Inc. (NASDAQ:ACOR), Hawthorne, N.Y. Product: Fampridine-SR Business: Autoimmune Molecular target: Potassium (K) channel Description: Sustained-release formulation of 4-aminopyrid...